GLP-1 Peptide Medications
GLP-1 Medications
Semaglutide, tirzepatide, and retatrutide represent three generations of GLP-1 based therapy — each more potent than the last. Here’s what separates them, how they work, and what the research actually shows.
Three Generations, One Class
Each medication builds on the last — adding receptor targets, increasing potency, and producing greater average weight loss in clinical trials.
How GLP-1 Medications Work
GLP-1 stands for glucagon-like peptide-1 — a hormone your gut naturally produces after eating. These medications mimic and amplify that signal with far greater potency and duration.
When you eat, your gut releases GLP-1 naturally. It signals your pancreas to release insulin, tells your brain you’re full, slows gastric emptying so food moves through your system more slowly, and suppresses glucagon — the hormone that raises blood sugar. The problem is that natural GLP-1 breaks down within minutes.
GLP-1 receptor agonists are engineered versions of this hormone designed to last days rather than minutes — and in the case of semaglutide, nearly a week per dose. The result is sustained appetite suppression, improved blood sugar regulation, and significant metabolic changes that go well beyond simple calorie restriction.
Average Weight Loss by Generation
Head-to-head comparison of average body weight reduction in Phase 3 clinical trials at maximum tolerated dose.
Each Medication, Up Close
Semaglutide was the medication that changed the conversation around obesity. Before Wegovy®’s approval in 2021, no drug had produced weight loss approaching 15% of body weight in clinical trials. That benchmark — previously associated only with bariatric surgery — fundamentally shifted how obesity is classified and treated.
- 1Appetite suppression — activates GLP-1 receptors in the hypothalamus, directly reducing hunger signaling and increasing satiety.
- 2Gastric slowing — delays stomach emptying, extending the feeling of fullness after meals.
- 3Insulin regulation — glucose-dependent insulin release reduces blood sugar spikes without hypoglycemia risk at therapeutic doses.
- 4Cardiovascular benefit — the SELECT trial established a 20% reduction in major adverse cardiac events, making semaglutide the first weight loss drug with a proven CV benefit.
Tirzepatide introduced a second receptor into the equation — GIP (glucose-dependent insulinotropic polypeptide) — producing meaningfully greater weight loss than semaglutide alone. The SURMOUNT trials showed average weight loss approaching 21–22%, with a significant proportion of patients losing 25% or more of body weight.
The addition of GIP signaling does more than amplify appetite suppression. GIP receptors in fat tissue appear to directly influence how the body stores and releases fat — a mechanism that semaglutide doesn’t access.
- 1Dual receptor activation — simultaneously activates GLP-1 and GIP receptors, producing synergistic appetite suppression that exceeds either pathway alone.
- 2Direct fat tissue effect — GIP receptors in adipose tissue influence fat storage and mobilization, adding a metabolic mechanism beyond appetite suppression.
- 3Improved insulin sensitivity — the GIP component contributes to insulin sensitization beyond the glucose-dependent insulin release shared with semaglutide.
- 4Shorter half-life advantage — ~5 days vs semaglutide’s ~7 days means faster clearance if side effects require a dose hold.
Retatrutide is the most potent weight loss compound to have completed Phase 2 clinical trials — and possibly the most significant development in metabolic medicine since tirzepatide. By adding a third receptor target — the glucagon receptor (GCGR) — it activates a pathway that directly increases energy expenditure, not just appetite suppression.
This distinction matters. Previous GLP-1 medications work primarily by making you eat less. Retatrutide also appears to make your body burn more — a fundamentally different and potentially more durable mechanism.
- 1Triple receptor activation — adds glucagon receptor agonism to the dual GIP/GLP-1 mechanism of tirzepatide, creating three simultaneous metabolic pathways.
- 2Increased energy expenditure — glucagon receptor activation directly increases the body’s resting energy burn — a mechanism absent in semaglutide and tirzepatide.
- 3Liver fat reduction — glucagon signaling accelerates hepatic fat oxidation, making retatrutide particularly relevant for NAFLD/NASH.
- 4Phase 3 data pending — Phase 3 TRIUMPH trials ongoing. If Phase 3 mirrors Phase 2 results, retatrutide will represent the most effective approved weight loss pharmacotherapy to date.
Full Comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Drug class | GLP-1 agonist | GIP/GLP-1 dual agonist | GIP/GLP-1/GCGR triple agonist |
| Avg weight loss | ~15% | ~20–22% higher | ~24%+ highest |
| FDA approval | Approved (2021) | Approved (2023) | Phase 3 / Pending |
| Dosing frequency | Once weekly | Once weekly | Once weekly |
| Half-life | ~7 days longest | ~5 days | ~6 days |
| Energy expenditure | Indirect (less eating) | Indirect + fat tissue | Direct (glucagon) unique |
| CV outcome data | Yes (SELECT trial) proven | Ongoing | Not yet available |
| NAFLD/liver fat | Modest reduction | Greater reduction | Strongest best |
| Compounded availability | Yes — widely available | Yes — widely available | Yes — limited |
| Typical concentrations | 2.5, 5 mg/mL | 17, 20 mg/mL | 10, 20 mg/mL |
Side Effects Overview
GLP-1 medications share a common side effect profile driven by their GI mechanism. Most are dose-dependent, transient, and manageable with slow titration.
- Nausea — most common, especially on escalation
- Vomiting — typically resolves within weeks
- Diarrhea or constipation
- Bloating and abdominal discomfort
- Heartburn / acid reflux
- Fatigue — often early in treatment
- Headache — typically transient
- Injection site reactions
- Hair thinning (telogen effluvium)
- Muscle loss with rapid weight loss
- Pancreatitis — monitor for severe abdominal pain
- Gastroparesis — persistent gastric slowing
- Thyroid C-cell tumors (animal data only)
- Gallbladder disease with rapid weight loss
- Slow titration is the single best prevention
- Smaller, lower-fat meals reduce nausea
- Stay well hydrated
- Resistance training preserves muscle mass